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Sorsby’s fundus dystrophy (SFD) is a dominantly in-
herited degenerative disease of the retina that leads to
loss of vision in middle age. It has been shown to be
caused by mutations in the gene for tissue inhibitor of
metalloproteinases-3 (TIMP-3). Five different mutations
have previously been identified, all introducing an extra
cysteine residue into exon 5 (which forms part of the
C-terminal domain) of the TIMP-3 molecule; however,
the significance of these mutations to the disease phe-
notype was unknown. In this report, we describe the
expression of several of these mutated genes, together
with a previously unreported novel TIMP-3 mutation
from a family with SFD that results in truncation of
most of the C-terminal domain of the molecule. Despite
these differences, all of these molecules are expressed
and exhibit characteristics of the normal protein, in-
cluding inhibition of metalloproteinases and binding to
the extracellular matrix. However, unlike wild-type
TIMP-3, they all form dimers. These observations, to-
gether with the recent finding that expression of TIMP-3
is increased, rather than decreased, in eyes from pa-
tients with SFD, provides compelling evidence that
dimerized TIMP-3 plays an active role in the disease
process by accumulating in the eye. Increased expres-
sion of TIMP-3 is also observed in other degenerative
retinal diseases, including the more severe forms of age-
related macular degeneration, the most common cause
of blindness in the elderly in developed countries. We
hypothesize that overexpression of TIMP-3 may prove to
be a critical step in the progression of a variety of de-
generative retinopathies.
Sorsby’s fundus dystrophy (SFD)1 is an autosomal, dominant
degenerative disease of the macula, typically leading to loss of
central vision in middle age (the fourth or fifth decade) (1). The
disease is characterized by extracellular deposits (drusen) and
thickening in Bruch’s membrane, the basement membrane sep-
arating the retinal pigment epithelium from its blood supply,
the choriocapillaris. This is accompanied by atrophy of the
choriocapillaris, retinal pigment epithelium, and photorecep-
tors and subretinal neovascularization that can lead to retinal
detachment. Although SFD is rare, it is of particular interest as
it closely resembles the more severe (exudative or “wet”) form
of age-related macular degeneration (AMD), the most common
cause of blindness in the elderly of developed countries.
SFD has been shown to be caused by mutations in the gene
for tissue inhibitor of metalloproteinases-3 (TIMP-3) (2). The
members of the TIMP family, of which there are currently four
(TIMPs 1–4) (3–6), are the natural inhibitors of matrix metal-
loproteinases (MMPs), a group of zinc-dependent endopepti-
dases that exist in both secreted and membrane-bound forms.
The balance between MMPs and TIMPs regulates remodeling
of the extracellular matrix (ECM) and thus plays a key role in
a wide range of physiological processes that include embryonic
development, connective tissue remodeling, wound healing,
glandular morphogenesis, and angiogenesis.
Structurally, TIMPs can be divided into two major domains,
each comprising three disulfide bonded loops (7, 8). The highly
conserved N-terminal domain has been shown to be sufficient
for MMP inhibition (9–11), whereas the C-terminal domains
are more divergent and appear to be important in imparting
individual differences in specificity to each TIMP family mem-
ber (12), including, for example, their different affinities for
pro-MMPs (the inactive precursors of MMPs) (13–16). Like-
wise, we have shown that a C-terminally deleted TIMP-3 is still
an effective MMP inhibitor, whereas its ability to bind to the
ECM, a unique feature of TIMP-3, largely resides in the C-
terminal domain (11).
With one recent exception (17), all previously described mu-
tations to TIMP-3 in SFD change residues in exon 5 (which
encodes the C-terminal domain of the molecule) into cysteines;
however, the role such mutations play in the disease process is
unknown. It was widely assumed that these mutations would
severely disrupt protein folding, leading to the conclusion that
the disease was probably attributable to insufficient expression
of TIMP-3 from the remaining normal allele. Nevertheless, the
possibility remained that the mutant protein itself may give
rise to the disease phenotype. Support for this latter hypothesis
was strengthened by recent work from our laboratory that
showed that the most common TIMP-3 mutation observed in
SFD, S181C, gave rise to a molecule that retained its ability to
both inhibit MMPs and localize to the ECM yet, unlike wild-
type TIMP-3, formed dimers (11).
This report describes the biochemical characterization of
several other TIMP-3 mutations, including the identification of
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an SFD family2 with a completely novel TIMP-3 mutation in
which a residue in exon 5 is changed to a stop codon, resulting
in the deletion of most of the C-terminal domain of the mole-
cule. These data provide strong evidence of an active role for
mutant TIMP-3 in SFD and a possible link to other degenera-
tive retinal diseases.
EXPERIMENTAL PROCEDURES
DNA Samples—Blood was obtained from three affected members
and one unaffected member of a recently identified SFD family, and
genomic DNA was extracted by standard methods. DNA samples from
normal individuals and a patient shown to have the S181C mutation
were also isolated as controls.
Polymerase Chain Reaction—Polymerase chain reaction primers for
exon 5 of the TIMP-3 gene were synthesized as described previously
(18). Amplifications were performed in 50-ml reactions using 15 pmol of
each primer, 200 mM dNTPs, 4% formamide, 500 ng of genomic DNA,
and 1–2 units of Taq DNA polymerase (Promega) in the recommended
buffer (50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 1.5 mM
MgCl2). Cycling was carried out on a Perkin-Elmer DNA Thermal
Cycler 480 as follows: initial denaturation at 94 °C for 4 min followed by
30 cycles of 1 min at 94 °C, 1 min at 55 °C, and 1 min 72 °C, with a final
extension at 72 °C for 10 min.
Restriction Digest and Single Strand Conformation Polymorphism
Analysis—After checking for successful amplification, 25 ml of each
reaction mix was digested with 6 units of PstI (New England Biolabs) in
the supplied buffer for 3–18 h at 37 °C. 10 ml of single strand confor-
mation polymorphism loading buffer (98% formamide, 10 mM EDTA,
20 mM NaOH, 0.05% bromphenol blue, 0.05% xylene cyanol) were added
to 10 ml of each digest, and the samples were denatured at 94 °C for 5
min, placed immediately on ice to reduce duplex formation, and then
loaded onto each of two gels: (a) 13 MDETM (FMC Corp.) in 0.63 TBE
buffer with 2% glycerol, and (b) 8% acrylamide (49:1 acrylamide:bisac-
rylamide) in 0.63 TBE. Gel a was run in 0.63 TBE at ambient tem-
perature for 18 h at 200 V. Gel b was run in 0.63 TBE at 4 °C for 16 h
at 170 V. Gels were silver-stained by standard methods.
DNA Sequencing—Polymerase chain reaction products amplified as
above, from an unaffected control and an affected patient, were se-
quenced using SequenaseTM polymerase chain reaction product se-
quencing kit (Amersham Pharmacia Biotech) and the forward primer.
Expression Plasmid Construction—Construction of pCI.neo vectors
(Promega) containing wild-type TIMP-3 and the S181C SFD mutant
has been described previously (11). S156C, G166C, and E139X were
constructed using the QuickChange (Stratagene, Cambridge, United
Kingdom) site-directed mutagenesis kit using the wild-type TIMP-3-
pCI.neo as a template and overlapping oligonucleotide primers contain-
ing the appropriate mutation. Plasmids for transfection were prepared
with Plasmid Mini or Maxi kits (Qiagen). All TIMP-3 constructs were
fully sequenced on an Applied Biosystems automated DNA sequencer to
confirm the changes and ensure that no further mutations had been
introduced.
COS-7 Cell Transfection—COS-7 cells were routinely cultured in
Dulbecco’s modified Eagle’s medium 1 10% fetal calf serum in a 37 °C,
5% CO2 humidified incubator. Transfections were performed by DEAE-
dextran/dimethyl sulfoxide shock (19) with the inclusion of 0.5% FCS in
the transfection solution. 48 h after transfection, the cells were trans-
ferred to serum-free Dulbecco’s modified Eagle’s medium and allowed to
grow for a further 48 h. Cells and ECM were then harvested according
to Ref. 20. However, for the Western blots, immediately after removing
the cells and prior to harvesting the ECM, duplicate plates were also
incubated for 60 min at room temperature with 10 mM freshly prepared
iodoacetamide to alkylate any free sulfhydryl groups. The protein
concentrations of the fractions were determined using the BCA protein
assay reagent (Pierce), and equal protein amounts were analyzed by
protease/substrate SDS-polyacrylamide gel electrophoresis.
Protease/Substrate SDS-Polyacrylamide Gel Electrophoresis (Re-
verse Zymography)—Samples were analyzed on 12 or 15% acrylamide
protease/substrate gels according to Ref. 21, except that phorbol myris-
tate acetate-stimulated U937 cell-conditioned media, at a final concen-
tration of 10% (v/v), was used as a source of gelatinase activity (22), and
gelatin was incorporated into the gel at a final concentration of
2.5 mg/ml. Following staining with Coomassie Brilliant Blue (Sigma),
inhibitory species were visualized as dark blue bands against a clear
background.
Immunoblotting—Reduced or nonreduced (heated for 10 min at 95 °C
with or without 2% 2-mercaptoethanol respectively) samples were sep-
arated on 12% SDS-polyacrylamide gel electrophoresis gels with bioti-
nylated molecular weight markers (Amersham Pharmacia Biotech)
prior to blotting onto polyvinylidene difluoride membrane (Pierce &
Warriner UK Ltd.) in 10 mM CAPS 1 10% methanol (pH 11.0) at 60mA
overnight. Membranes were blocked by incubation with Tris-buffered
saline, pH 7.5 (TBS) 1 6% skim milk powder 1 0.2% Tween-20 for 6 h.
Rabbit anti-TIMP-3 (first loop) antibody (Sigma) was diluted (1:1000) in
TBS 1 6% skim milk powder 1 0.05% Tween-20 (antibody dilution
buffer) and incubated with the blots overnight at 4 °C. Membranes were
washed extensively in TBS and TBS 1 0.05% Tween-20, prior to incu-
bation with horseradish peroxidase-labeled secondary antibody
(DAKO) (1:6,000) and streptavidin-horseradish peroxidase conjugate
(1:1, 500) (Amersham Pharmacia Biotech) in antibody dilution buffer
for 1 h. Membranes were then washed as before and developed with
SuperSignal West Pico chemiluminescent substrate (Pierce).
RESULTS
Genetic Mapping
Three single strand conformation polymorphism band pat-
terns were found: one in the normal control and unaffected
family member, one in the three affected individuals, and a
third in an individual known to have the common S181C mu-
tation. Direct DNA sequencing showed a G to T transversion in
one allele in the first base of codon 139 in the three affected
individuals (Fig. 1), resulting in a TAG termination codon
replacing the normal GAG glutamic acid codon (E139X).
The presence of the same E139X mutation in patient III5
(Fig. 2), as well as the mother and daughter (patients II2 and
III1 respectively), indicates that it is not a de novo mutation in
this latter family but must have come from either I1 or I2.
Biochemical Characterization
S156C, G166C, and S181C SFD Mutations—Mock-trans-
fected COS-7 cells (pCI.neo alone) express 2 or 3 functional
MMP inhibitors in the ECM with approximate molecular
masses in the range of 23–29 kDa (Fig. 3, lane A). These masses
correspond to those previously reported for unglycosylated and
glycosylated TIMP-3, respectively (23), and the inhibitors are
presumed to be endogenously expressed TIMP-3. This conclu-
sion is confirmed by Western blotting (Fig. 4a, lane A) and by
the fact that these bands are greatly intensified in COS-7 cells
transfected with wild-type TIMP-3 (Figs. 3 and 4a, lane B).
ECM from cells transfected with the various SFD mutants
all showed up to four additional higher molecular mass MMP-
inhibitory species in the range of approximately 45–60 kDa
that also cross-reacted with the anti-TIMP-3 antibody (Figs. 3
and 4a, lanes C–E). There were, however, differences in the
intensities of the higher mass bands between the three mu-
tants tested, which was particularly apparent on the (more
2 M. P. Clarke, K. W. Mitchell, N. McKie, M. D. Barker, and J. A.
Goodship, manuscript in preparation.
FIG. 1. Section from a sequencing gel of DNA from a normal
and SFD patient. All of the affected members of the new SFD family
have a thymidine instead of a guanosine in one allele at the first base
of codon 139, resulting in the transformation of a glutamate residue into
a stop codon.
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sensitive) Western blots (Fig. 4a, lanes C–E). S156C formed
four bands, with the 50-kDa band predominating; G166C ran
mainly at approximately 55 and 60 kDa; and S181C had a
particularly predominant band at about 45 kDa, with lower
intensity bands at approximately 50, 55, and 60 kDa. Treat-
ment of the ECM with iodoacetamide prior to harvesting had
no effect on the formation of these higher molecular mass
species.
None of these higher molecular mass species were apparent
on Western blots of the same samples run under reducing
conditions (Fig. 4b, lanes C–E). In this case, however, there was
an increase in the intensity of staining of the 23–29-kDa bands
relative to mock-transfected cells.
E139X SFD Mutation—In contrast to the reverse zymo-
grams and Western blots of the previously described SFD mu-
tations, those of nonreduced ECM from COS-7 cells transfected
with the E139X SFD construct did not reveal any novel high
molecular mass species, although the 27-kDa species appeared
to show some increase in intensity relative to the 24-kDa spe-
cies on the Western blot (Fig. 5a, lane C). However, when the
same sample was run under reducing conditions (Fig. 5b,
lane C), there was a marked decrease in intensity of the 27-kDa
species, with a corresponding appearance of a novel anti-
TIMP-3 immunoreactive species at approximately 16 kDa. This
corresponds almost exactly to the predicted molecular mass of
monomeric E139X protein (15.9 kDa). The reduced molecule
ran as a single species in keeping with the fact that the N-
glycosylation site, which lies close to the C terminus of the
wild-type molecule (see Fig. 6), is absent in this mutant. There
was no change in size of the wild-type control under the same
conditions (Fig. 5b, lane B).
DISCUSSION
We have identified an entirely novel TIMP-3 mutation in a
family with Sorsby’s fundus dystrophy. Instead of a transition
to a cysteine, a glutamic acid residue is changed to a stop codon,
resulting in a TIMP-3 molecule lacking a large part of the
C-terminal domain (see Fig. 6). Despite this difference, the
phenotype of the disease in these patients, including age of
onset, is not particularly distinguishable from previously de-
scribed SFD families (clinical details to be reported elsewhere),
and this appears to be reflected in the biochemical character-
istics of the mutant protein.
We have previously shown that the S181C SFD mutation
gives rise to an MMP-inhibitory, ECM-localized TIMP-3 dimer
(11). Here, we confirm that this also appears to be the case for
two other SFD mutations, S156C and G166C, and it is more
than likely that the other two observed SFD mutations, G167C
and Y168C, being adjacent to G166, behave likewise. There
were, however, some differences in the pattern of expression of
S156C and G166C, relative to S181C, in that expression levels
of these mutants were somewhat less than those observed for
S181C, and the pattern of higher molecular mass species var-
ied between the different mutants. In theory, the different
combinations of the three monomer forms of TIMP-3 (which are
due to differential glycosylation (11)) could give rise to up to six
different dimers. The fact that for each mutant different
dimers appeared to predominate may be a reflection of the
relative positions of the free sulfhydryl residue and carbohy-
drate moieties. In S181C, for example, the potentially unpaired
cysteine is in close proximity to the glycosylation site (Asn184),
FIG. 2. Pedigree of the SFD family. f and E, unaffected male and
female, respectively; l , affected female; slashed square and slashed
circle, deceased male and deceased female, respectively, affected status
unknown; 3, mutation testing completed and consistent with affected
status.
FIG. 3. Reverse zymogram of ECM from COS-7 cells trans-
fected with normal and previously reported SFD mutations of
TIMP-3. A, mock-transfected; B, wild-type TIMP-3; C, S156C-TIMP-3;
D, G166C-TIMP-3; E, S181C-TIMP-3. Positions of molecular mass
markers (in kDa) are indicated on the left.
FIG. 4. Western blots of ECM from COS-7 cells transfected with
normal and previously reported SFD mutations of TIMP-3. a,
nonreduced gel; b, reduced gel. Lane A, mock-transfected; lane B, wild-
type TIMP-3; lane C, S156C-TIMP-3; lane D, G166C-TIMP-3; lane E,
S181C-TIMP-3. Positions of molecular mass markers (in kDa) are in-
dicated on the left.
FIG. 5. Western blots of ECM from COS-7 cells transfected with
normal and E139X-TIMP-3. a, nonreduced gels; b, reduced gels. Lane
A, mock-transfected; lane B, wild-type TIMP-3; lane C, E139X-TIMP-3.
Positions of molecular mass markers (in kDa) are indicated on the left.
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possibly explaining why the smaller, less glycosylated dimer
predominates.
Despite the fact that the new SFD mutation described herein
results in truncation of most of the C-terminal domain of the
molecule (which we have previously shown contributes signif-
icantly to the ability of TIMP-3 to localize to the ECM (11)),
E139X still forms an ECM localized dimer. Although this new
mutation does not give rise to an extra cysteine residue, it does
result in one that is potentially unpaired (Cys122; see Fig. 6),
explaining the ability of the molecule to dimerize. Several
features of the mutant may contribute to ECM localization.
First, it lacks an N-glycosylation site. We have shown previ-
ously that glycosylation of TIMP-3 decreases its apparent af-
finity for the ECM, presumably by masking basic residues (11).
Second, truncation still leaves a small section (18 residues) of
the C-terminal domain that may contribute disproportionately
to ECM binding. Third, dimerization will increase avidity. The
fact that the E139X dimer ran somewhat anomalously at ap-
proximately 27 kDa (rather than the expected 32 kDa), in a
position identical to that of the glycosylated TIMP-3 monomer,
precluded confirmation that this molecule is also a functional
MMP-inhibitor; however, this is very likely to be the case, as
TIMP-3 truncated at Asn121 still retains its ability to inhibit
MMPs (11).
The fact that this entirely novel SFD mutation is also a
localized dimer provides compelling evidence that dimer forma-
tion is critical to the disease process because point mutations to
residues other than cysteines could equally well disrupt protein
folding if the haploinsufficiency model was correct. It has re-
cently been reported that an intron 4/exon 5 splice site muta-
tion in TIMP-3 also gives rise to the SFD phenotype, but with
a delayed age of onset (the seventh rather than fourth or fifth
decade) (17). Although the consequences of such splice site
mutations cannot be predicted, one possibility is the skipping of
the fifth exon. This would give rise to a TIMP-3 molecule
lacking the whole of the C-terminal domain but retaining an
unpaired cysteine residue (Cys122) and therefore the potential
to dimerize. Our data predict that such a molecule would be a
functional MMP inhibitor but would show poor localization to
the ECM (11). Reduced ECM localization could provide a pos-
sible explanation for the delayed age of onset of the disease in
these patients.
Assuming, therefore, that the mutant TIMP-3 contributes
actively to the disease process, how might dimer formation
affect the function of the molecule? Several possibilities exist.
For example, a TIMP-3 dimer would potentially be able to
cross-link membrane-bound proteins, such as the metallopro-
teinases membrane type 1-MMP or tumor necrosis factor-a
converting enzyme (TACE) (24, 25). Whether dimerization of
such molecules is functionally significant is currently un-
known; however, binding in this way to membrane type 1-MMP
may inhibit its ability to activate progelatinase A via TIMP-2
(24). Interestingly, the recently identified membrane type
5-MMP also appears to exist in a dimeric form (26). Alterna-
tively, dimerization at the C terminus may alter the binding of
this domain to target molecules, such as pro-MMPs; this would
certainly be the case for the E139X mutant, in which this
domain is largely deleted. Another alternative is that dimer-
ization may simply inhibit normal turnover of the molecule.
Support for this latter possibility has recently come from im-
munohistochemical analyses of eyes from SFD patients. Such
eyes show an increased deposition of TIMP-3, particularly in
Bruch’s membrane (27). This does not definitively prove that
the mutated protein itself is accumulating; it is possible that
the mutant TIMP-3 induces overexpression from the normal
allele. However, it is strong evidence against the haploinsuffi-
ciency model. In either case, as both normal and mutant mol-
ecules show MMP-inhibitory activity, the mutation may act by
decreasing cell matrix turnover leading to the observed thick-
ening of Bruch’s membrane that characterizes the disease.
Such thickening could in itself lead to nutrient deprivation and
thus retinopathy and also stimulate neovascularization of the
choroid.
An alternative possibility is that accumulated TIMP-3 has a
more direct effect on the retina by triggering apoptosis. TIMP-3
has been shown to trigger cell cycle arrest and apoptosis in a
variety of cell types by both MMP-dependent and MMP-inde-
pendent mechanisms (28–30).
Abnormal expression of TIMP-3 in Bruch’s membrane also
occurs in AMD and another degenerative retinal disease, sim-
plex retinitis pigmentosa (27, 31, 32). Although neither AMD
nor retinitis pigmentosa is associated with heritable mutations
in TIMP-3 (33, 34), the similarities in disease phenotype, par-
ticularly between SFD and the more severe forms of AMD,
make it tempting to speculate that TIMP-3 is a causal agent
linking these diseases. It is likely that localization of TIMP-3 to
the ECM occurs through its interaction with glycosaminogly-
cans (35). One possible mechanism for TIMP-3 accumulation in
AMD may, therefore, be binding to products of advanced pro-
tein glycosylation (advanced glycation end products) associated
with old age. Accumulation of advanced glycation end products
is greatly accelerated in diabetes, and pharmacological inhibi-
tion of advanced glycation end product formation in diabetic
animals prevents many of the complications of long term dia-
betes, including retinopathy (reviewed in Ref. 36). It will be
interesting to determine whether TIMP-3 accumulation is also
associated with this disease.
In summary, we have shown that dimerization of TIMP-3 is
a common factor linking the various mutations that are asso-
ciated with Sorsby’s fundus dystrophy. The fact that such
dimers are functional, together with evidence for TIMP-3 ac-
cumulation in SFD, suggests that dimerization inhibits turn-
over of the molecule, which then plays an active role in the
disease process. There is also a possibility that TIMP-3 accu-
mulation, albeit by different mechanisms, is a causative agent
of other degenerative retinal diseases. If this proves to be the
case, then therapies directed at preventing or reversing
FIG. 6. Diagrammatic representation of TIMP-3 showing key
residues. The positions of disulfide bonds are based on those deduced
for TIMP-1 (7, 8). CHO denotes the N-glycosylation site. Residues
mutated in SFD are shown in solid black, and the E139X mutation is
indicated with an arrow.
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TIMP-3 localization may offer hope of treatment for a variety of
currently incurable and debilitating eye diseases.
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